2020
DOI: 10.1007/978-3-030-64610-3_80
|View full text |Cite
|
Sign up to set email alerts
|

Investigation of Drug Eluting Stents Performance Through in silico Modeling

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 20 publications
0
3
0
Order By: Relevance
“…With the application and invention of coronary stents, a dramatic decrease in bypass surgeries was reported. Drug-eluting stents (DESs) were developed to replace conventionally used bare metal stents (BMSs), as they caused complications such as reblockage of vessels, called in-stent restenosis. , After stent implantation, approximately 20–30% of patients experienced in-stent restenosis . This post-implant complication is due to vascular smooth cell proliferation, migration, and growth of the arterial inner wall because of the insufficient biocompatibility of stent material .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…With the application and invention of coronary stents, a dramatic decrease in bypass surgeries was reported. Drug-eluting stents (DESs) were developed to replace conventionally used bare metal stents (BMSs), as they caused complications such as reblockage of vessels, called in-stent restenosis. , After stent implantation, approximately 20–30% of patients experienced in-stent restenosis . This post-implant complication is due to vascular smooth cell proliferation, migration, and growth of the arterial inner wall because of the insufficient biocompatibility of stent material .…”
Section: Introductionmentioning
confidence: 99%
“…With the application and invention of coronary stents, a dramatic decrease in bypass surgeries was reported. Drug-eluting stents (DESs) were developed to replace conventionally used bare metal stents (BMSs), 3 as they caused complications such as reblockage of vessels, called in-stent restenosis. 4 , 5 After stent implantation, approximately 20–30% of patients experienced in-stent restenosis.…”
Section: Introductionmentioning
confidence: 99%
“…For patients affected by CVD, the implantation of a drug-eluting stent (DES) is currently the most commonly accepted treatment [ 6 ]. DESs have demonstrated superiority to bare-metal stents (BMSs) concerning reduced neointimal hyperplasia (restenosis) [ 7 ], however, delayed endothelization and an increased risk of late stent thrombosis was detected with the first generation of these devices [ 8 , 9 ].…”
Section: Introductionmentioning
confidence: 99%